Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB1CZ8)

Drug Name

Guanfacine extended release Drug Info

Synonyms

Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitamide MEA; Hydroxyethylpalmitamide; N-palmitoylethanolamine; N-(2-Hydroxyethyl)palmitamide; Palmitic acid monoethanolamide; Palmitoyl-EA; Loramine P 256; Palmitoyl ethanolamide; Palmidrolum; palmitylethanolamide; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Palmidrolum [INN-Latin]; UNII-6R8T1UDM3V; Palmitinsaeure-beta-hydroxyethylamid; Monoethanolamine palmitic acid amide; NSC 23320; hexadecanoyl ethanolamide; Anandamide (16:0)

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]

Cross-matching ID

PubChem CID: 4671
ChEBI ID: CHEBI:71464
CAS Number: CAS 544-31-0
TTD Drug ID: DMB1CZ8

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor Alpha-2 (ADRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[9]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[10]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[11]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[9]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[12]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[13]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[14]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[15]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[16]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[18]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[19]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[20]
LY-2828360	DMO8IEZ	Pain	MG30-MG3Z	Phase 2	[20]
APD371	DM3XT5V	Crohn disease	DD70	Phase 2	[21]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[22]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[23]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[24]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[25]
Tedalinab	DM58J7E	Pain	MG30-MG3Z	Phase 1	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting G-protein coupled receptor 55 (GPR55)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIO-017	DMYHK3Y	Angelman syndrome	LD90.0	Phase 1	[27]
N-oleoylethanolamide	DMJQ4L7	Discovery agent	N.A.	Investigative	[3]
[3H]CP55940	DMU7FC5	Discovery agent	N.A.	Investigative	[3]
lysophosphatidylinositol	DMETM3R	Discovery agent	N.A.	Investigative	[28]
O-1602	DM9VISB	Discovery agent	N.A.	Investigative	[29]
abnormal cannabidiol	DMV6DAO	Discovery agent	N.A.	Investigative	[3]
O-arachidonoyl ethanolamine	DML0P72	Discovery agent	N.A.	Investigative	[3]
CID1172084	DMK6YOP	Discovery agent	N.A.	Investigative	[30]
CID16020046	DMLWZRT	Discovery agent	N.A.	Investigative	[31]
2-arachidonyl glyceryl ether	DM2H8TV	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Glucose-dependent insulinotropic receptor (GPR119)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DS-8500	DMUXIRM	Diabetic complication	5A2Y	Phase 2	[32]
SAR-260093	DMBJU2G	Type-2 diabetes	5A11	Phase 2	[33]
GSK1292263	DMDMXKQ	Gastric adenocarcinoma	2B72	Phase 2	[34]
BMS-903452	DM7JW0B	Type-2 diabetes	5A11	Phase 1	[35]
APD-597	DM36FOG	Type-2 diabetes	5A11	Phase 1	[36]
DA-1241	DMPJA64	Type 2 diabetes	5A11	Phase 1	[37]
APD668	DMN8R2U	Type-2 diabetes	5A11	Discontinued in Phase 1	[38]
PSN821	DMGEWUS	Type-2 diabetes	5A11	Terminated	[39]
N-oleoylethanolamide	DMJQ4L7	Discovery agent	N.A.	Investigative	[28]
lysophosphatidylinositol	DMETM3R	Discovery agent	N.A.	Investigative	[40]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cannabinoid receptor 2 (CNR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[41]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[44]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[45]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[46]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[47]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[48]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[49]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Claudin-5 (CLDN5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[52]
Glycine	DMIOZ29	Allergic rhinitis	CA08.0	Approved	[53]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[54]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[55]
CS-600G	DM1PV4Y	N. A.	N. A.	Phase 3	[56]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[57]
LY294002	DMY1AFS	Neuroblastoma	2D11.2	Phase 1	[58]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[53]
JWH-133	DM1DEYU	Discovery agent	N.A.	Investigative	[59]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Claudin-3 (CLDN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[52]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[64]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[65]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[60]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[66]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[67]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Apolipoprotein B-100 (APOB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[68]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[69]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[71]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[68]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[72]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[68]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[73]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Aquaporin-4 (AQP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[6]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]
Ammonia	DMOEVK6	Coronary artery disease	BA80	Approved	[76]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[77]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[78]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[79]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[80]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[81]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[82]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[83]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[84]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[85]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[86]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[87]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[88]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[86]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[1]
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Agonist	[2]
G-protein coupled receptor 55 (GPR55)	TTNET8J	GPR55_HUMAN	Agonist	[3]
Glucose-dependent insulinotropic receptor (GPR119)	TT7QNVC	GP119_HUMAN	Agonist	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Protein Interaction/Cellular Processes	[5]
Aquaporin-4 (AQP4)	OTA9MYD5	AQP4_HUMAN	Gene/Protein Processing	[6]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Regulation of Drug Effects	[7]
Cannabinoid receptor 2 (CNR2)	OTYP9P43	CNR2_HUMAN	Protein Interaction/Cellular Processes	[8]
Claudin-3 (CLDN3)	OT71MN9S	CLD3_HUMAN	Gene/Protein Processing	[6]
Claudin-5 (CLDN5)	OTUX60YO	CLD5_HUMAN	Gene/Protein Processing	[6]

------------------------------------------------------------------------------------

References

1	Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
2	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
5	Increased plasma concentrations of palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: an in vitro study. Atherosclerosis. 2005 Sep;182(1):47-55. doi: 10.1016/j.atherosclerosis.2005.01.043.
6	Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018. doi: 10.1093/ibd/izz017.
7	Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis. J Clin Invest. 2018 Aug 31;128(9):4044-4056. doi: 10.1172/JCI96817. Epub 2018 Aug 13.
8	Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 2000 Jan 7;275(1):605-12. doi: 10.1074/jbc.275.1.605.
9	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
10	Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
11	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
12	Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
13	Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
14	Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
15	Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
16	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
17	Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
18	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
19	Company report (Gwpharm)
20	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
21	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
23	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
24	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
25	Clinical pipeline report, company report or official report of Roche
26	Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010
27	Clinical pipeline report, company report or official report of Biom Therapeutics
28	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
29	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev. 2010 Dec;62(4):588-631.
30	Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47.
31	A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66.
32	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
33	GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.
34	Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494.
35	Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508.
36	Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5.
37	ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health.
38	Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil. Arena Pharmaceuticals, Inc. FEBRUARY 07, 2006.
39	Clinical pipeline report, company report or official report of Astellas Pharma (2011).
40	Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
41	Cloning and pharmacological characterization of the dog cannabinoid CB?receptor. Eur J Pharmacol. 2011 Nov 1;669(1-3):24-31. doi: 10.1016/j.ejphar.2011.08.002. Epub 2011 Aug 19.
42	hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Front Mol Neurosci. 2020 Jul 6;13:119. doi: 10.3389/fnmol.2020.00119. eCollection 2020.
43	Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
44	Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
45	Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
46	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
47	Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
48	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
49	Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
50	Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
51	Arsenic downregulates tight junction claudin proteins through p38 and NF-B in intestinal epithelial cell line, HT-29. Toxicology. 2017 Mar 15;379:31-39. doi: 10.1016/j.tox.2017.01.011. Epub 2017 Jan 20.
52	Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact. 2009 May 15;179(2-3):185-91. doi: 10.1016/j.cbi.2008.11.009. Epub 2008 Nov 21.
53	Effects of glyphosate and aminomethylphosphonic acid on an isogeneic model of the human blood-brain barrier. Toxicol Lett. 2019 Apr;304:39-49. doi: 10.1016/j.toxlet.2018.12.013. Epub 2018 Dec 31.
54	Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
55	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
56	Loxoprofen enhances intestinal barrier function via generation of its active metabolite by carbonyl reductase 1 in differentiated Caco-2?cells. Chem Biol Interact. 2021 Oct 1;348:109634. doi: 10.1016/j.cbi.2021.109634. Epub 2021 Sep 8.
57	Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
58	Involvement of claudin-5 in H(2)S-induced acute lung injury. J Toxicol Sci. 2020;45(5):293-304. doi: 10.2131/jts.45.293.
59	Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci. 2012 Mar 21;32(12):4004-16. doi: 10.1523/JNEUROSCI.4628-11.2012.
60	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
61	Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
62	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
63	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
64	The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
65	Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
66	Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
67	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
68	Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
69	Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1999 Sep 15;84(6):655-9. doi: 10.1016/s0002-9149(99)00411-7.
70	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
71	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
72	Glucosamine-induced endoplasmic reticulum stress promotes ApoB100 degradation: evidence for Grp78-mediated targeting to proteasomal degradation. Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):571-7. doi: 10.1161/01.ATV.0000154142.61859.94. Epub 2004 Dec 23.
73	Aluminum-induced mitochondrial dysfunction leads to lipid accumulation in human hepatocytes: a link to obesity. Cell Physiol Biochem. 2007;20(5):627-38. doi: 10.1159/000107546.
74	Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
75	In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
76	Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. Metab Brain Dis. 2010 Mar;25(1):17-21.
77	Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. J Clin Psychopharmacol. 2012 Jun;32(3):394-7. doi: 10.1097/JCP.0b013e31825370f4.
78	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
79	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
80	Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
81	Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
82	Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
83	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
84	Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
85	Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
86	Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
87	Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
88	Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.